AI assistant
INVION LIMITED — Capital/Financing Update 2026
Mar 22, 2026
65148_rns_2026-03-22_b29ea04a-2a5f-44ab-ab0d-6c8dd4b055bb.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Appendix 3B - Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
Announcement Summary
Entity name INVION LIMITED
Announcement Type
New announcement
Date of this announcement 23/3/2026
The Proposed issue is:
A placement or other type of issue
Total number of +securities proposed to be issued for a placement or other type of issue
| Maximum Number of | ||
|---|---|---|
| ASX +security code | +Security description | +securities to be issued |
| IVXO | OPTION EXPIRING 30-JUN-2027 | 5,000,000 |
| IVX | ORDINARY FULLY PAID | 5,000,000 |
Proposed +issue date 13/5/2026
Refer to next page for full details of the announcement
Appendix 3B - Proposed issue of securities
1 / 5
Appendix 3B - Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
Part 1 - Entity and announcement details
1.1 Name of +Entity
INVION LIMITED
We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.
If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).
1.2 Registered Number Type
ACN
Registration Number
094730417
1.3 ASX issuer code
IVX
1.4 The announcement is
New announcement
1.5 Date of this announcement
23/3/2026
1.6 The Proposed issue is:
A placement or other type of issue
Appendix 3B - Proposed issue of securities
2 / 5
Appendix 3B - Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
Part 7 - Details of proposed placement or other issue
Part 7A - Conditions
7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis? Yes 7A.1a Conditions Approval/Condition Date for determination Is the date estimated or ** Approval actual? received/condition met? +Security holder approval 13/5/2026 Estimated
Comments
Part 7B - Issue details
Is the proposed security a 'New Will the proposed issue of this class' (+securities in a class that is +security include an offer of not yet quoted or recorded by ASX) attaching +securities? or an 'Existing class' (additional No securities in a class that is already quoted or recorded by ASX)? Existing class
Details of +securities proposed to be issued
ASX +security code and description
IVXO : OPTION EXPIRING 30-JUN-2027
Number of +securities proposed to be issued
5,000,000
Offer price details
Are the +securities proposed to be issued being issued for a cash consideration? No
Please describe the consideration being provided for the +securities
Offered as a short-term incentive to Mr Thian Chew, Executive Chair and CEO, to align his interests with the performance of the Company, in particular having regard to the long term strategic goals of the Company to grow and development its portfolio of drug candidates and subject to the approval from shareholders of the expanded intellectual property licence with RMW Cho Group Limited and a successful equity capital raising of at least $3 million before end FY2026.
Appendix 3B - Proposed issue of securities
3 / 5
Appendix 3B - Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities
0.026000
Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? Yes
Is the proposed security a 'New Will the proposed issue of this class' (+securities in a class that is +security include an offer of not yet quoted or recorded by ASX) attaching +securities? or an 'Existing class' (additional No securities in a class that is already quoted or recorded by ASX)? Existing class
Details of +securities proposed to be issued
ASX +security code and description
IVX : ORDINARY FULLY PAID
Number of +securities proposed to be issued
5,000,000
Offer price details
Are the +securities proposed to be issued being issued for a cash consideration? No
Please describe the consideration being provided for the +securities
Offered as a short-term incentive to Mr Thian Chew, Executive Chair and CEO, to align his interests with the performance of the Company, in particular having regard to the long term strategic goals of the Company to grow and development its portfolio of drug candidates and subject to the approval from shareholders of the expanded intellectual property licence with RMW Cho Group Limited and a successful equity capital raising of at least $3 million before end FY2026.
Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities
0.078000
Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? Yes
Part 7C - Timetable
7C.1 Proposed +issue date
13/5/2026
Appendix 3B - Proposed issue of securities
4 / 5
Appendix 3B - Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
Part 7D - Listing Rule requirements
7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1? Yes
7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1 13/5/2026
7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue? Yes
7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules? No
7D.4 Will any of the +securities to be issued be subject to +voluntary escrow? No
Part 7E - Fees and expenses
7E.1 Will there be a lead manager or broker to the proposed issue? No
7E.2 Is the proposed issue to be underwritten? No
7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue No material fees.
Part 7F - Further Information
7F.01 The purpose(s) for which the entity is issuing the securities
Offered as a short-term incentive to Executive Chair and CEO, to align his interests with the performance of the Company, subject to approval of shareholders of expanded intellectual property licence and a capital raising of at least $3m before end FY2026.
7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? No
7F.2 Any other information the entity wishes to provide about the proposed issue
7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of: The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)
Appendix 3B - Proposed issue of securities
5 / 5